Epigenomics in Veterinary Cancer: What Sits Between the DNA and the Diagnosis
Cutting Edge Diagnostics · Canine, Feline · Oncology
Genomics tells you the sequence. Proteomics tells you what is being made. Epigenomics tells you what is being allowed to happen — and what is being silenced. It occupies the regulatory layer between DNA and gene expression, and it is increasingly recognized as a critical dimension of cancer biology that neither genomics nor proteomics fully captures. In veterinary oncology, epigenomics is an emerging field with real diagnostic and prognostic potential, and understanding what it measures helps place it alongside the other molecular tools now entering clinical research.
What epigenomics measures
Epigenomics is the study of heritable changes in gene expression that do not involve alterations to the underlying DNA sequence. The two most studied epigenetic mechanisms in cancer are DNA methylation and histone modification. Both regulate which genes are accessible for transcription at any given time — effectively controlling whether a gene is switched on, switched off, or operating at reduced capacity.
DNA methylation is the addition of a methyl group to cytosine residues, typically at CpG dinucleotides. In normal tissue, methylation patterns are precisely regulated and cell-type specific. In cancer, these patterns are disrupted: tumor suppressor genes are frequently silenced by hypermethylation of their promoter regions — effectively switching them off without any mutation to the gene itself — while global hypomethylation destabilizes the genome and activates oncogenic elements. This methylation reprogramming is a near-universal feature of malignancy and occurs early in tumor development, often before genetic mutations accumulate.
Histone modifications — acetylation, methylation, phosphorylation, and ubiquitination of histone proteins around which DNA is wound — control chromatin accessibility and therefore gene expression. Cancer cells frequently show aberrant histone modification patterns that silence tumor suppressor pathways and maintain the open chromatin state of oncogenic programs. These modifications are reversible, which is one reason epigenetic targets have attracted interest as therapeutic candidates.
Why epigenomics matters for cancer biology
The significance of epigenetic disruption in cancer extends beyond gene regulation. Methylation patterns carry information about the cell of origin — because epigenetic marks are established during cellular differentiation and are largely preserved in tumor cells derived from that lineage. This is the foundation of methylation-based cancer detection and tissue-of-origin classification, which is now being applied in liquid biopsy platforms and multi-cancer early detection research in human medicine.
In the context of the relationship between DNA, proteomics, and epigenomics: if DNA gives you the potential and proteomics gives you the reality, epigenomics tells you which parts of the potential are being accessed and which are being locked away. A tumor suppressor gene that is intact in the DNA sequence but silenced by promoter methylation will produce no functional protein — an invisible alteration that genomic sequencing misses but methylation analysis reveals. Conversely, an oncogene that is not mutated but is epigenetically activated through loss of normal silencing may drive tumor growth without any detectable genomic aberration.
Current applications in canine oncology
Canine diffuse large B-cell lymphoma (DLBCL) has been one of the most studied tumors in veterinary epigenomics. Aberrant DNA methylation patterns have been identified in canine lymphoma that parallel those described in human DLBCL, including hypermethylation of tumor suppressor gene promoters involved in cell cycle regulation, apoptosis, and DNA repair. These findings suggest shared epigenetic mechanisms across species and reinforce the validity of the dog as a comparative oncology model for human lymphoma research.
Canine mammary tumors have also been examined epigenomically, with studies identifying differential methylation patterns between benign and malignant tumors and between primary tumors and metastases. Methylation signatures that distinguish invasive from non-invasive mammary carcinoma are of particular interest given the clinical challenge of predicting metastatic behavior in histologically intermediate-grade lesions.
Osteosarcoma epigenomics in dogs has revealed global hypomethylation and specific promoter methylation changes affecting genes involved in differentiation and apoptosis. Some of these alterations correlate with histologic features and clinical outcome, raising the possibility that methylation profiling could add prognostic information beyond what current grading and staging provide.
Current applications in feline oncology
Feline epigenomics research is less mature than canine but is growing. Feline oral squamous cell carcinoma — discussed previously in this blog as one of the most consistently aggressive oral malignancies in cats — has been the subject of epigenomic investigation aimed at understanding its resistance to treatment. Aberrant methylation of genes involved in EGFR signaling, cell adhesion, and invasion have been identified, consistent with the molecular picture of FOSCC as a deeply invasive, treatment-resistant tumor. These findings complement the proteomic data discussed in a prior post and suggest that epigenetic silencing of regulatory genes may contribute to the aggressive phenotype.
Feline injection-site sarcoma has also been examined for epigenetic alterations, with early data pointing toward methylation changes in tumor suppressor pathways that parallel findings in canine FISS and in human sarcomas of similar histogenesis. The intersection between epigenomics and the immune microenvironment in FISS — particularly the relationship between epigenetic silencing and immune evasion — is an active area of investigation.
Epigenomics and liquid biopsy: a natural convergence
One of the most compelling near-term applications of epigenomics in veterinary oncology is its integration with liquid biopsy. Circulating tumor DNA carries the methylation signature of the tumor from which it was shed. Methylation-based detection of ctDNA is more specific than mutation-based approaches for some tumor types — because methylation patterns are cell-type specific in a way that somatic mutations are not, they can in principle identify both that cancer is present and where in the body it originated.
This is the basis of multi-cancer early detection platforms in human medicine that use methylation profiling of cell-free DNA to simultaneously screen for multiple cancer types from a single blood draw. Translating this to veterinary species requires large, well-annotated methylation reference datasets across tumor types in dogs and cats — datasets that are being assembled now through academic veterinary oncology research programs. The technical capability exists; the reference data is the rate-limiting step.
Therapeutic implications: epigenetics as a drug target
Unlike genetic mutations, epigenetic alterations are reversible. This has made them attractive therapeutic targets. DNA methyltransferase inhibitors (such as azacitidine and decitabine, used in human hematologic malignancies) reactivate silenced tumor suppressor genes by blocking maintenance methylation. Histone deacetylase (HDAC) inhibitors restore normal histone acetylation patterns and reactivate epigenetically silenced genes. Both drug classes have been investigated in veterinary oncology, with early-phase studies in canine lymphoma and other hematologic malignancies showing biological activity.
These drugs are not yet standard of care in veterinary oncology, and their use remains investigational in most settings. But the principle they illustrate is important: epigenetic drivers of cancer are targetable in a way that many genetic drivers are not, and the identification of epigenetic alterations in a tumor is not purely academic — it may ultimately point toward therapeutic vulnerabilities that conventional chemotherapy does not address.
Where this is going
The trajectory of epigenomics in veterinary oncology follows a similar arc to proteomics: research findings are accumulating, reference datasets are being built, and the gap between discovery and clinical deployment is narrowing. The most immediate near-term application is methylation-based liquid biopsy, where the infrastructure being developed for ctDNA detection provides a natural vehicle for methylation profiling. Tissue-based epigenomic profiling of FFPE samples is technically feasible and will enable retrospective studies on existing tumor archives. And the therapeutic angle — identifying epigenetically silenced pathways as drug targets — adds a clinical urgency that purely diagnostic applications do not have.
Epigenomics is not yet a routine part of veterinary cancer diagnosis. But it is providing answers to questions that genomics and proteomics alone cannot fully address — explaining why tumors that look similar behave differently, why some cancers resist treatment without obvious resistance mutations, and where in the regulatory landscape the disease is actually operating. That explanatory power is what will drive its eventual clinical integration.
Eric Snook, DVM, PhD, DACVP — Vetopathy. Histopathology remains the diagnostic foundation. Emerging molecular layers like epigenomics are most powerful when they extend and refine what tissue morphology already tells us.